Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related mortality in the United States and has only recently achieved a 5-yr survival rate of 10%. This dismal prognosis reflects the remarkable capacity of PDAC to effectively adapt to and resist therapeutic intervention. In this review, we discuss recent advances in our understanding of the biological underpinnings of PDAC and their implications as targetable vulnerabilities in this highly lethal disease.

中文翻译：

---

胰腺癌治疗耐药性的生物学基础

胰腺导管腺癌 (PDAC) 是美国癌症相关死亡率的主要原因，最近才达到 10% 的 5 年生存率。这种令人沮丧的预后反映了 PDAC 有效适应和抵抗治疗干预的非凡能力。在这篇综述中，我们讨论了我们对 PDAC 生物学基础的理解的最新进展，以及它们作为这种高度致命疾病的可靶向弱点的影响。